Exicure inc XCUR.US 總覽分析
美股醫療保健
(XCUR 無簡報檔)
XCUR 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
XCUR 近期報酬表現
3.67%
Exicure inc
4.57%
同產業平均
3.26%
S&P500
與 XCUR 同產業的標的表現
- FBRX Forte biosciences inc價值 1 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
XCUR 公司資訊
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.